Niebauer J, Pflaum C D, Clark A L, Strasburger C J, Hooper J, Poole-Wilson P A, Coats A J, Anker S D
Department of Cardiac Medicine, Royal Brompton Hospital and National Heart and Lung Institute, London, England, United Kingdom.
J Am Coll Cardiol. 1998 Aug;32(2):393-7. doi: 10.1016/s0735-1097(98)00226-5.
Recent studies of growth hormone supplementation in chronic heart failure have been associated with variable results. Acquired abnormalities of biochemical parameters of the growth hormone insulin-like growth factor I axis have been associated with severe chronic heart failure. There are suggestions of an acquired growth hormone resistance with deficient insulin-like growth factor I in some patients.
Therefore, we set out to investigate the clinical and functional status and the degree of cytokine and neurohormonal alteration of chronic heart failure patients with deficient insulin-like growth factor I responses.
Patients with chronic heart failure were divided into two groups according to their insulin-like growth factor I levels (classified according to the manufacturer's assay range in normal controls): low insulin-like growth factor I <104 (n = 20; 89 +/- 9.6 ng/ml), and normal/high >104 ng/ml (n = 32; 169 +/- 52 ng/ml). Between groups there was no difference in age (low versus high: 65.3 +/- 12.1 versus 61.6 +/- 9.1 years, p = 0.21), body mass index, aerobic capacity (peak oxygen consumption: low versus high: 15.5 +/- 5.2 versus 17.3 +/- 6.3 mL/kg/min, p = 0.23), left ventricular ejection fraction, New York Heart Association classification.
During quadriceps strength testing, patients with low insulin-like growth factor I had reduced absolute strength (-24%), and strength per unit area muscle (- 14%) than patients with normal/high insulin-like growth factor I. Leg muscle cross-sectional area was lower in the low insulin-like growth factor I group (-12% and -13% for right and left legs, respectively). These alterations were accompanied by increased levels of growth hormone (+145%), tumor necrosis factor-alpha (+46%), cortisol/ dehydroepiandrosterone ratio (+60%), noradrenaline (+49%) and adrenaline (+136%) (all at least p < 0.05).
Patients with low insulin-like growth factor I levels show signs of altered body composition, cytokine and neuroendocrine activation, to a greater extent than patients with normal/high levels.
近期关于慢性心力衰竭患者补充生长激素的研究结果各异。生长激素胰岛素样生长因子I轴生化参数的后天异常与严重慢性心力衰竭相关。有迹象表明,部分患者存在获得性生长激素抵抗且胰岛素样生长因子I缺乏。
因此,我们着手研究胰岛素样生长因子I反应缺乏的慢性心力衰竭患者的临床和功能状态以及细胞因子和神经激素改变程度。
根据慢性心力衰竭患者的胰岛素样生长因子I水平(按照制造商在正常对照中的检测范围分类)将其分为两组:低胰岛素样生长因子I组<104(n = 20;89±9.6 ng/ml),正常/高胰岛素样生长因子I组>104 ng/ml(n = 32;169±52 ng/ml)。两组在年龄(低胰岛素样生长因子I组与高胰岛素样生长因子I组:65.3±12.1岁与61.6±9.1岁,p = 0.21)、体重指数、有氧运动能力(峰值耗氧量:低胰岛素样生长因子I组与高胰岛素样生长因子I组:15.5±5.2与17.3±6.3 mL/kg/min,p = 0.23)、左心室射血分数、纽约心脏协会分级方面无差异。
在股四头肌力量测试中,低胰岛素样生长因子I组患者的绝对力量(-24%)和单位面积肌肉力量(-14%)低于正常/高胰岛素样生长因子I组患者。低胰岛素样生长因子I组的腿部肌肉横截面积较低(右腿和左腿分别降低-12%和-13%)。这些改变伴随着生长激素水平升高(+145%)、肿瘤坏死因子-α升高(+46%)、皮质醇/脱氢表雄酮比值升高(+60%)、去甲肾上腺素升高(+49%)和肾上腺素升高(+136%)(均至少p < 0.05)。
与正常/高胰岛素样生长因子I水平的患者相比,低胰岛素样生长因子I水平的患者在身体成分改变、细胞因子和神经内分泌激活方面表现更为明显。